Researchers at Winship Cancer Institute of Emory University found that COVID-19 vaccines are much less effective for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia, particularly those ages 65 and older. After vaccination, many of these patients produced low or no antibodies that bind or neutralize SARS-CoV-2 and its variants of concern, particularly Omicron.
University of Texas Southwestern researchers developed a blood test to predict which nonalcoholic fatty liver disease patients are most likely to develop hepatocellular carcinoma.
Researchers from Cedars-Sinai Cancer analyzed patient samples and studies conducted in animal models to identify a novel role for the IL-27 signaling pathway in hepatocellular carcinoma.
FDA has granted accelerated approval to Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.
FDA granted Fast Track designation for IK-930, a novel TEAD inhibitor targeting the Hippo signaling pathway, in patients with unresectable NF2-deficient malignant pleural mesothelioma.
Cullinan Oncology Inc. and Taiho Pharmaceutical Co. Ltd. completed their agreement to collaborate on the U.S. development of CLN-081/TAS6417, a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer (The Cancer Letter, May 13, 2022).
FDA announced it will issue marketing denial orders to all JUUL e-cigarette products. The products must be removed from shelves across the country or risk enforcement action, as FDA has ruled they do not meet the public health standard required to be authorized for sale.
As she was interviewing for the director’s job at the George Washington Cancer Center, Julie E. Bauman was asked what her biggest fear would be.
NCI and Cancer Research UK have awarded $100 million in total funding through the Cancer Grand Challenges program, supporting research into solid tumors in children, cachexia, extrachromosomal DNA, and tumor development.
In the next phase of the Cancer Moonshot, NCI will focus on investing in the development and testing of new modalities, including multi-cancer early detection assays, and fostering diversity in oncology, NCI Acting Director Douglas R. Lowy said at a joint meeting of the Board Of Scientific Advisors and the National Cancer Advisory Board.
